BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Core Insights - BioCardia, Inc. has been granted Patent No: 12,036,371 for a method of accessing the left atrium with a multi-directional steerable catheter, which will expire in 2035, enhancing shareholder value [1][2][3] Company Overview - BioCardia is focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its biotherapeutic platforms including CardiAMP® and CardiALLO™ [4] Market Insights - The transseptal access systems market generated $941.3 million in revenue in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.3%, reaching $2.1 billion by 2033 [2][7] - The Morph DNA technology allows for improved catheter performance and navigation, addressing a longstanding technical issue in transseptal procedures [2][3] Product Development - BioCardia plans to utilize the new introducer technology platform for various biotherapeutic interventions related to heart failure, refractory angina, and acute myocardial infarction, targeting approximately 500,000 transseptal procedures performed annually in the U.S. [3]